<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00599807</url>
  </required_header>
  <id_info>
    <org_study_id>PP00B-114864</org_study_id>
    <secondary_id>2007DR4347</secondary_id>
    <nct_id>NCT00599807</nct_id>
  </id_info>
  <brief_title>Zurich Multiple Endpoint Vitamin D Trial in Knee OA Patients</brief_title>
  <official_title>Role of Vitamin D in Secondary Prevention of Knee Osteoarthritis: A Double-blind Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Harvard School of Public Health (HSPH)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tufts University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-year double-blind randomized controlled trial in 287 community-dwelling&#xD;
      individuals age 60 years or older undergoing uni-lateral total knee replacement due to severe&#xD;
      OA of the knee.We compare an oral dose of 2000 IU vitamin D3 per day to 800 IU. The primary&#xD;
      endpoints are pain and disability related to rehabilitation of the operated knee,and related&#xD;
      to the expected high prevalence of OA in the contra-lateral knee. Secondary endpoints are&#xD;
      change in 25(OH)D levels, muscle strength, balance, lower extremity function, the rate of&#xD;
      falls, bone density and bone quality, bone metabolism, general pain, fall-related fractures,&#xD;
      body composition, blood-pressure, major cardiovascular events, blood glucose-insulin levels,&#xD;
      executive cognitive function, rate of upper respiratory tract infections / all infections,&#xD;
      tooth loss, dental health, health care utilization, number and size of facial skin keratosis,&#xD;
      and radiographic progression of the non-operated knee. Pain and disability will be assessed&#xD;
      by the pain and function subscales of the Western Ontario- McMaster Universities&#xD;
      Osteoarthritis Index (WOMAC). Randomization will be stratified by WOMAC function prior to&#xD;
      surgery, radiological evidence for OA in the contra-lateral knee, and hospital. Clinical&#xD;
      visits will take place at baseline (6-8 weeks after TKR), at 6, 12, 18 and 24 months of&#xD;
      treatment. In addition, all individuals will receive a phone call every 2 month to assess&#xD;
      adverse outcomes and compliance to treatment, supported by a hotline for immediate report of&#xD;
      adverse events.&#xD;
&#xD;
      Statistical power: We expect more than 80% power with 200 participants completing their 24&#xD;
      month follow-up, and 260 participants completing their 12 month follow-up.&#xD;
&#xD;
      This is a trial with medicinal product.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pain and function of the operated and non-operated knee</measure>
    <time_frame>0, 6,12,18, 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of falls</measure>
    <time_frame>0, 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>strength, balance, function, physical activity</measure>
    <time_frame>0,6,12,18,24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone density, bone quality</measure>
    <time_frame>0, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body composition</measure>
    <time_frame>0, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>0,12,24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of teeth</measure>
    <time_frame>0, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost, health care utilization</measure>
    <time_frame>0,6,12,18,24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>facial skin keratosis (number and size)</measure>
    <time_frame>0, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognitive function</measure>
    <time_frame>0, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>depression, mental health</measure>
    <time_frame>0,12,24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting blood glucose - insulin levels</measure>
    <time_frame>0,12,24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of upper respiratory infections and number of any infections</measure>
    <time_frame>0, 6,12,28,24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone metabolism</measure>
    <time_frame>0,6,12,18,24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>radiographic progression of the non-operated knee</measure>
    <time_frame>0, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>general pain</measure>
    <time_frame>0,6,12,18,24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>0,6,12,18,24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">273</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>1: 2000 IU D3/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2000 IU vitamin D3 taken orally each day for 2 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: 800 IU D3 / day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>800 IU vitamin D3 taken orally each day for 2 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3 (cholecalciferol)</intervention_name>
    <description>the intervention is a dietary supplement comparing the current standard (800 IU) to the current safe upper limit (2000 IU)</description>
    <arm_group_label>1: 2000 IU D3/day</arm_group_label>
    <arm_group_label>2: 800 IU D3 / day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Unilateral knee replacement due to knee osteoarthritis&#xD;
&#xD;
          -  Age 60+ years&#xD;
&#xD;
          -  German language skills&#xD;
&#xD;
          -  community dwelling&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bi-lateral knee replacement or hip replacement planned in the trial period, or in the&#xD;
             previous 6 months&#xD;
&#xD;
          -  Chronic steroid intake&#xD;
&#xD;
          -  Serum calcium corrected for serum albumin &gt; 2.6 mmol/l&#xD;
&#xD;
          -  GFR &lt; 30 ml/min&#xD;
&#xD;
          -  Severe visual or hearing impairment&#xD;
&#xD;
          -  Inflammatory arthritis&#xD;
&#xD;
          -  Malabsorption&#xD;
&#xD;
          -  High alcohol intake&#xD;
&#xD;
          -  Sarcoidosis, primary hyperparathyroidism&#xD;
&#xD;
          -  History of kidney stones, lymphoma&#xD;
&#xD;
          -  Chemotherapy for cancer in the previous 12 months&#xD;
&#xD;
          -  Hemiplegia&#xD;
&#xD;
          -  Morbus Parkinson&#xD;
&#xD;
          -  Unable to walk 3 meters prior to surgery&#xD;
&#xD;
          -  Bisphosphonate, parathyroid hormone , fluoride or calcitonine therapy in the last 6&#xD;
             months&#xD;
&#xD;
          -  Zolendronate in the last year&#xD;
&#xD;
          -  M. Paget (Ostitis deformans)&#xD;
&#xD;
          -  Vitamin D3 intake more than 800IU/d over more than 1 month&#xD;
&#xD;
          -  stay on a sunny location for more than 6 weeks per year&#xD;
&#xD;
          -  heart failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heike Bischoff-Ferrari, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Centre on Aging and Mobility</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Zurich, Centre on Aging and Mobility</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>January 10, 2008</study_first_submitted>
  <study_first_submitted_qc>January 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2008</study_first_posted>
  <last_update_submitted>October 27, 2014</last_update_submitted>
  <last_update_submitted_qc>October 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

